These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
200 related articles for article (PubMed ID: 18952545)
1. Practical considerations for multiple myeloma: an overview of recent data and current options. Lonial S Clin Lymphoma Myeloma; 2008 Aug; 8 Suppl 4():S144-8. PubMed ID: 18952545 [TBL] [Abstract][Full Text] [Related]
2. Novel agents for relapsed and/or refractory multiple myeloma. Thomas SK; Richards TA; Weber DM Cancer J; 2009; 15(6):485-93. PubMed ID: 20010168 [TBL] [Abstract][Full Text] [Related]
5. Diagnosis and the current trends in multiple myeloma therapy. DmoszyĆska A Pol Arch Med Wewn; 2008 Oct; 118(10):563-6. PubMed ID: 19112817 [TBL] [Abstract][Full Text] [Related]
6. Thalidomide, lenalidomide and bortezomib in the management of newly diagnosed multiple myeloma. Laubach JP; Schlossman RL; Mitsiades CS; Anderson KC; Richardson PG Expert Rev Hematol; 2011 Feb; 4(1):51-60. PubMed ID: 21322778 [TBL] [Abstract][Full Text] [Related]
7. Treatment of relapsed and refractory myeloma. Kaufman J; Gleason C; Lonial S Curr Hematol Malig Rep; 2009 Apr; 4(2):99-107. PubMed ID: 20425421 [TBL] [Abstract][Full Text] [Related]
8. The treatment of relapsed and refractory multiple myeloma. Richardson P; Mitsiades C; Schlossman R; Ghobrial I; Hideshima T; Chauhan D; Munshi N; Anderson K Hematology Am Soc Hematol Educ Program; 2007; ():317-23. PubMed ID: 18024646 [TBL] [Abstract][Full Text] [Related]
9. The use of novel agents in the treatment of relapsed and refractory multiple myeloma. Laubach JP; Mahindra A; Mitsiades CS; Schlossman RL; Munshi NC; Ghobrial IM; Carreau N; Hideshima T; Anderson KC; Richardson PG Leukemia; 2009 Dec; 23(12):2222-32. PubMed ID: 19741729 [TBL] [Abstract][Full Text] [Related]
10. New drugs for myeloma. Richardson PG; Mitsiades C; Schlossman R; Munshi N; Anderson K Oncologist; 2007 Jun; 12(6):664-89. PubMed ID: 17602058 [TBL] [Abstract][Full Text] [Related]
11. Treatment options for relapsed and refractory multiple myeloma. Lonial S; Mitsiades CS; Richardson PG Clin Cancer Res; 2011 Mar; 17(6):1264-77. PubMed ID: 21411442 [TBL] [Abstract][Full Text] [Related]
16. Evolving role of novel agents for maintenance therapy in myeloma. Magarotto V; Palumbo A Cancer J; 2009; 15(6):494-501. PubMed ID: 20010169 [TBL] [Abstract][Full Text] [Related]
18. Advances in treatment for relapses and refractory multiple myeloma. Richards T; Weber D Med Oncol; 2010 Jun; 27 Suppl 1():S25-42. PubMed ID: 20213220 [TBL] [Abstract][Full Text] [Related]
19. (Bortezomib plus lenalidomide/thalidomide)- vs. (bortezomib or lenalidomide/thalidomide)-containing regimens as induction therapy in newly diagnosed multiple myeloma: a meta-analysis of randomized controlled trials. Wang A; Duan Q; Liu X; Ding K; Han Y; Zhu W; Cai X; Wu J; Sun Z Ann Hematol; 2012 Nov; 91(11):1779-84. PubMed ID: 22773209 [TBL] [Abstract][Full Text] [Related]